secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001517022-24-000033
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia extends vadadustat supply agreement with STA to 2029
-----------------------------------------------------------

- Amendment #2 extends Supply Agreement term to April 2, 2029 (five additional years).
- Agreement covers manufacturing of vadadustat drug substance for commercial purposes.
- Volume-based pricing structure was amended; no financial terms disclosed.
- Original Supply Agreement dated April 2, 2020, previously amended April 15, 2021.
- Contract manufacturer STA Pharmaceutical Hong Kong Limited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/0001517022-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/akba-20241504xwuxiamendment.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer